is retatrutide a glp 1 agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy Curious about the differences between

Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial

Discussion While the overall number of GLP-1 RA exposures increased during the study period, outcomes were largely benign, with the most common being no effect

Acknowledgements This work was supported by funding from the Funds for innovative interdisciplinary oncologic research of the City of Vienna [Project Number: 21041]

p = 0.002)

The Evolving Story: Why Dual Agonism Isn't the Final Word The metabolic landscape shifted dramatically when Tirzepatide , a first-in-class dual GIP and GLP-1 receptor agonist, received FDA approval

Burra P, Becchetti C, Germani G